晚期NSCLC免疫一线治疗策略.pptx

晚期NSCLC免疫一线治疗策略.pptx

《晚期NSCLC免疫一线治疗策略.pptx》由会员分享，可在线阅读，更多相关《晚期NSCLC免疫一线治疗策略.pptx（32页珍藏版）》请在冰豆网上搜索。

晚期NSCLC免疫一线治疗策,从略：

ASCO会议到临床实践,AdvancesofImmunotherapyin1LNSCLC,PD-L150%,PD-L11%,PD-L11%,Non-squamous&squamous,Non-squamous,Squamous,AllPD-L1,AllPD-L1,Monotherapy,ChemotherapyCombinations,AntiangiogenicCombanations,CIT+CIT,Non-squamous&squamous,AllPD-L1,PD-L11%,NCCNClinicalPracticeGuidelinesinOncology（NCCNGuidelines）Non-SmallCellLungCancerVersion4P.l2a0n2ch0ardD,etal.AnnOncol.2018Oct1;29（Suppl4）:

iv192-iv237.GUIDELINESOFCHINESESOCIETYOFCLINICALONCOLOGY（CSCO）NON-SMALLCELLLUNGCANCER2020,用药方案,双,药,帕博利珠单抗vs.含铂双,药,泰圣奇vs.顺铂/卡铂+培美曲塞/吉西他,滨,TPS50%：

26.3vs.14.2个,TPS50%：

20vHsR.12.2个,TC3或IC3,W20T.2：

vs.13.1个,月HR,P0=.509.0106,月HR0.65P=0.00110.3vs.6.0,OSPFS（月）ORR（%）,45vs.28,月P0=.609.0037.1vs.6.4（TPS50%）40vs.32（TPS50%）,TPS50%118（76.6）vs.135（90.0）48（31.2）vs.80（53.3）20（13.2）vs.1（0.7）,8.1vs.5.0（TC3或IC3）38.3vs.28.6（TC3或IC3）173（60.5）vs.224（85.2）37（12.9）vs.116（44.1）19（6.6）vs4（1.5）*,不良事件n（%）,任意级别TRAE3级TRAE3级irAE,399（63）vs.,151533（179.08）vs.252（41）51（8.0%）vs.9（1.5）,NSCLC一线免疫单药研究,用药方案,帕博利珠单抗vs.含铂双药,ABCPvsACPvs,BCP,Nivolumab3mg/kgQ2W+,Ipilimumab1mg/kgQ6W（）,4cycles,（4cycles）,moQ3W,ITT-WT:

19.5vs14.7vs.Che,Nivolumab360mgQ3W+,Ipilimumab1mg,vs.CheQm6oWQ（3W2cy（cl4e）cycles）,P0.01HR0.80,TWCT1/:

2/3或IC1/2/34-vs,1622.5vs.24.,TC0和IC0-WT:

14.8v16s.9.vs.14.1,OS,HRP0.0,ITT：

22vs.10.7个月PD,0.56%:

NR1,10.1,PDL115-409%:

21.18v2s.v1s,PDL11%17.2vs10.2,HRP0.007,PDL11%17.1vs.14.9,PD0.7917.2vs.12.2,L11%HR0.62,HR,ITT人群15.6vs.10.9,0.66,PD15.8vs10.9HR0.64,L11%,PD16.8vs9.8HR0.62,NSQL1171v%s.11.9,HR0.69SQ14.5vs.9.1HR0.62,PFS,9.0vs4.9,8.3vs6.8,5.1vs.5.6,NSCLC一线免疫联合用药研究,1）GhandiL,etal.NEJM.16April2018.2）GadgeelS,etal.PresentedatASCO2019.Abstract9013.3）Rodriguez-AbreuD.PresentedatASCO2020.Abstract9582.4）Paz-AresL,etal.PresentedatASCO2018.Abstract105.5）Paz-Ares,etal.NEnglJMed2018;379:

2040-2051.6）Paz-AresL,etal.PresentedatESMO2019.AbstractLBA82.7）PetersS,etal.PresentedatESMO2019.AbstractLBA4.8）HellmanMet,al.NEJM.28Sept2019.9）RamalingamS,etal.PresentedatASCO2020.Abstract9500.10）ReckM,etal.PresentedatASCO2020.Abstract9501.,一线非小细胞肺癌主要临床研究数据比较（2020ASCO摘要公布）,IMpower150:

Phase3studyofACPorABCPvsBCPinchemotherapy-naivepatientswithmetastaticnon-squamousNSCLC,FedericoCappuzzo.2020ASCOAbstract9587.,Co-primaryendpoints:

PFSintheITT-WTpopulationPFSintheTeff-highWTpopulationOSintheWTpopulation.,PFSandPSintheITTpopulationIndependentreviewfacilityassessedPFSintheWTpopulationInvestigator-assessedPFSinthePD-L1expressionsubgroupsintheWTpopulationORRandDORintheWTpopulationSafetyintheITTpopulation,Atezolizumab+carboplatinc+paclitaxel（ACP）4or6cycles,Atezolizumab+bevacizumab+carboplatinpacl+itaxel（ABCP）,Atezolizumab,Maintenancetherapy（nocrossoverpermitted）,Bevacizumab+carboplatin+paclitaxel（BCP）4or6cyclesKeysecondaryendpoints,Atezolizumabb+evacizumab,Bevacizumab,TreatedwithatezolizumabuntilPDperRECIST1.1orlossofclinicalbenefitand/orTreatedwithbevacizumabuntilPDperRECIST1.1,Survivalup,StageIVorrecurrentmetastaticnon-squamousNSCLCChemotherapynaiveTumortissueforbioamvarilkaebrletestingAnyPD-L1IHCstatusStratificationfactors:

SexPD-L1IHCexpressionLivermetastasesN=1202,R,1:

1:

1,IMpower150demonstratedstatisticallysignificantandcmlienaicnainllgyfulimprovementswithABCPvsBCPinPFSandOS,SocinskiMA,etal.NEnglJMed.2018Jun14;378（24）2288-2301.,Investigator-AssessedPFSintheWTPopulation,OSintheWTPopulation,IMpower150:

ExploratoryAnalysisofBrainMetastasesDevelopment,Thebevacizumab-containingarmsofABCPandBCPhadcomparable,lowerratesofnewbrainlesiondevelopmentonstudyAtrendtowarddelayeddevelopmentofnewbrainlesionswasobservedwithABCPNonewsafetysignalswereobservedinthisexploratoryanalysisRateofNewBrainLesionsintheITTPopulationTTDofNewBrainLesionsintheITTPopulation,Thisreportfocusesonexploratoryanalyses,includingrateandtimetodevelopment（TTD）ofnewbrainmetastasesintheITTpopulation,regardlessofthepresenceofbrainmetastasesatbaseline,aswellassafetyinpatientswithandwithoutbrainmetastasesFedericoCappuzzo.2020ASCOAbstract9587.,HR=0.68,11.90%,7.00%,18%16%14%12%,IMpower150:

Exploratoryefficacyanalysisinpatientswithbulkydisease*,ExploratoryefficacyanalysesincludedPFS,OS,ORR,timetoresponse（TTR）inthesesubgroups;safetywasalsoassessed.OutcomesarereportedforpatientsenrolledintheABCPvsBCP,arms.,*patientswithhightumorburdenorlargesizeRobertJotte.2020ASCO,Withaminimumfollow-upof32.4moths（datacutoff:

Sep13,2019）,ABCPshowedimprovedOS,PFSandORRvsBCPinpatientswithhighandlowdiseaseburden.HighdiseaseburdendidnotimpactTTR.ThesafetyprofileofABCPwascomparablebetweenITT-WT（noEGFRorALKalterations）patientsandhighdiseaseburdensubgroups.,CheckMate227Part1:

Three-yearupdateo